NasdaqGS:SVRABiotechs
Savara (SVRA) Is Up 6.5% After Multi-Region Accelerated Reviews Granted for MOLBREEVI Therapy
Savara Inc. recently announced that the U.K. MHRA accepted its Marketing Authorisation Application for MOLBREEVI in autoimmune PAP under Accelerated Review, while the therapy is simultaneously under Priority Review by the U.S. FDA and active review by the EMA.
This cluster of fast-track designations across major regulators underscores MOLBREEVI’s potential as a first-in-class inhaled GM-CSF therapy for a rare, serious lung disease.
We’ll now examine how this multi-region accelerated review...